Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Viatris Inc

Healthcare US VTRS

14.08USD
-0.14(0.98%)

Last update at 2026-03-10T20:08:00Z

Day Range

14.0514.52
LowHigh

52 Week Range

8.5413.49
LowHigh

Fundamentals

  • Previous Close 14.22
  • Market Cap12371.17M
  • Volume8862586
  • P/E Ratio-
  • Dividend Yield4.61%
  • EBITDA4733.40M
  • Revenue TTM15361.20M
  • Revenue Per Share TTM12.82
  • Gross Profit TTM 7031.90M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 2813.20M -664.40000M -721.20000M 154.40M 298.40M
Minority interest - - - - -
Net income 2078.60M -1269.10000M -669.90000M 16.80M 352.50M
Selling general administrative 4179.10M 4529.20M 3344.00M 2563.60M 2441.00M
Selling and marketing expenses - - - - -
Gross profit 6497.00M 5575.50M 3796.70M 3897.60M 4001.60M
Reconciled depreciation 3027.60M 4506.50M 2216.10M 2019.30M 2109.90M
Ebit 418.80M -4205.50000M -113.40000M -1369.00000M -1318.70000M
Ebitda 3446.40M 301.00M 2102.70M 650.30M 791.20M
Depreciation and amortization 3027.60M 4506.50M 2216.10M 2019.30M 2109.90M
Non operating income net other - - - - -
Operating income 418.80M -4205.50000M -113.40000M -1369.00000M 905.60M
Other operating expenses 14607.00M 17591.10M 12049.00M 10806.40M 10577.80M
Interest expense 592.40M 636.20M 497.80M 517.30M 542.30M
Tax provision 734.60M 604.70M -51.30000M 137.60M -54.10000M
Interest income - - - - -
Net interest income -592.40000M -636.20000M -497.80000M -517.30000M -542.30000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 734.60M 604.70M -51.30000M 137.60M -54.10000M
Total revenue 16262.70M 17886.30M 11946.00M 11500.50M 11433.90M
Total operating expenses 4841.30M 5280.30M 3899.70M 3203.50M 3145.50M
Cost of revenue 9765.70M 12310.80M 8149.30M 7602.90M 7432.30M
Total other income expense net 2394.40M 3541.10M -607.80000M 1523.40M -15.40000M
Discontinued operations - - - - -
Net income from continuing ops 2078.60M -1269.10000M -669.90000M 16.80M 352.50M
Net income applicable to common shares 2078.60M -1269.10000M -669.90000M 16.80M 352.50M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 47685.50M 50022.20M 54842.80M 61553.00M 31255.50M
Intangible assets 19181.10M 22607.10M 26134.20M 29683.20M 11649.90M
Earning assets - - - - -
Other current assets 3638.60M 1811.20M 1957.60M 1230.50M 552.00M
Total liab 27218.10M 28949.90M 34350.10M 38598.90M 19371.70M
Total stockholder equity 20467.40M 21072.30M 20492.70M 22954.10M 11883.80M
Deferred long term liab - - - - -
Other current liab 4142.80M 3403.20M 8006.90M 2426.20M 4061.00M
Common stock 12.20M 12.10M 12.10M 12.10M 6.10M
Capital stock 12.20M 12.10M 12.10M 12.10M 6.10M
Retained earnings 4639.70M 5175.60M 3688.80M 5361.20M 6031.10M
Other liab - 4007.10M 4547.70M 5377.30M 2412.60M
Good will 9867.10M 10425.80M 12113.70M 12347.00M 9590.60M
Other assets - 2976.10M 5692.00M 3197.00M 761.30M
Cash 993.60M 1259.90M 701.20M 844.40M 475.60M
Cash and equivalents - - - - -
Total current liabilities 7777.40M 6746.20M 9884.40M 10562.90M 5569.10M
Current deferred revenue 226.80M 925.90M -1056.10000M 3340.90M -1061.90000M
Net debt 17386.30M 18014.40M 20893.40M 25264.40M 12246.80M
Short term debt 2026.40M 1259.10M 1877.50M 3450.10M 1508.10M
Short long term debt 1934.70M 1250.50M 1877.50M 3357.20M 567.50M
Short long term debt total 18379.90M 19274.30M 21594.60M 26108.80M 12722.40M
Other stockholder equity 18562.90M 18645.80M 18536.10M 18438.80M 7643.80M
Property plant equipment - 3283.80M 3479.40M 3783.50M 2404.20M
Total current assets 12228.80M 10635.40M 10902.90M 12867.50M 6757.30M
Long term investments 1142.00M 1091.40M 0.00000M 47.90M 92.20M
Net tangible assets - -11960.60000M -17755.20000M -19076.10000M -9356.70000M
Short term investments 86.30M 212.60M 233.80M 203.50M 109.10M
Net receivables 4040.60M 3814.50M 4266.40M 4843.80M 3058.80M
Long term debt 16188.10M 18015.20M 19717.10M 22429.20M 11214.30M
Inventory 3469.70M 3519.50M 3977.70M 5471.90M 2670.90M
Accounts payable 1381.40M 1158.00M 1056.10M 1345.70M 1061.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2747.40000M -2761.20000M -1744.30000M -858.00000M -1797.20000M
Additional paid in capital - - - - -
Common stock total equity - - - 12.10M 6.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1568.40M 1052.80M 5692.00M 676.00M 58.20M
Deferred long term asset charges - - - - -
Non current assets total 35456.70M 39386.80M 43939.90M 48685.50M 24498.20M
Capital lease obligations 248.40M 262.00M 287.60M 322.40M 252.40M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 1520.50M -0.40000M -301.10000M -525.40000M -1210.40000M
Change to liabilities 170.20M -70.40000M -82.70000M -96.30000M 220.30M
Total cashflows from investing activities 1520.50M -117.80000M -301.10000M -525.40000M -1210.40000M
Net borrowings -3280.10000M -2099.10000M -401.30000M -1102.90000M -631.70000M
Total cash from financing activities -3877.90000M -3012.00000M -605.70000M -1169.00000M -1090.90000M
Change to operating activities -618.30000M -666.50000M 46.00M 63.50M -177.90000M
Net income 2078.60M -1269.10000M -669.90000M 16.80M 352.50M
Change in cash 556.30M -143.80000M 358.90M 101.80M 19.40M
Begin period cash flow 706.20M 850.00M 491.10M 389.30M 369.90M
End period cash flow 1262.50M 706.20M 850.00M 491.10M 389.30M
Total cash from operating activities 2952.60M 3016.90M 1231.80M 1803.70M 2341.70M
Issuance of capital stock 3.30M - - - -
Depreciation 3027.60M 4506.50M 2216.10M 2019.30M 2109.90M
Other cashflows from investing activities - - - - -
Dividends paid 581.60M 399.00M 399.00M 399.00M 399.00M
Change to inventory -259.50000M -427.60000M -741.90000M -512.90000M -547.60000M
Change to account receivables -240.30000M 59.30M 78.70M -20.00000M 340.10M
Sale purchase of stock - - 0.00000M - -432.00000M
Other cashflows from financing activities 362.90M 1588.30M -8849.00000M -60.50000M 2506.30M
Change to netincome -1057.50000M 2877.10M 702.50M 456.00M 289.60M
Capital expenditures 443.00M 509.40M 681.20M 406.00M 1195.60M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -922.60000M -1804.80000M -696.30000M -507.80000M -189.00000M
Stock based compensation 116.40M 111.20M 79.20M 56.80M -3.30000M
Other non cash items -1321.50000M 797.40M 515.90M 411.20M 335.90M
Free cash flow 2509.60M 2507.50M 550.60M 1397.70M 1146.10M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VTRS
Viatris Inc		 -0.14 0.98% 14.08 - 4.10 0.87 0.66 1.99 8.71
ZTS
Zoetis Inc		 -1.87 1.53% 120.49 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.56 2.23% 25.64 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.64 2.02% 128.01 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.14 0.77% 18.21 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc

1000 Mylan Boulevard, Canonsburg, PA, United States, 15317

Key Executives

Name Title Year Born
Mr. Robert J. Coury Exec. Chairman 1961
Mr. Michael Goettler CEO & Exec. Director 1968
Mr. Rajiv Malik Pres & Exec. Director 1961
Mr. Sanjeev Narula Chief Financial Officer 1961
Mr. Anthony Mauro Pres of Developed Markets 1973
Mr. Sanjeev Kumar Sethi Chief Operating Officer 1967
Mr. Paul B. Campbell Chief Accounting Officer, Sr. VP & Corp. Controller 1967
Ms. Melissa Trombetta Head of Global Investor Relations NA
Mr. Brian S. Roman Global Gen. Counsel 1970
Mr. David Bayles Chief Compliance Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.